摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

tert-butyl 3-(4-fluorophenyl)-4-oxopiperidine-1-carboxylate | 632352-74-0

中文名称
——
中文别名
——
英文名称
tert-butyl 3-(4-fluorophenyl)-4-oxopiperidine-1-carboxylate
英文别名
——
tert-butyl 3-(4-fluorophenyl)-4-oxopiperidine-1-carboxylate化学式
CAS
632352-74-0
化学式
C16H20FNO3
mdl
——
分子量
293.338
InChiKey
CWIQZKCVLBDSNM-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.4
  • 重原子数:
    21
  • 可旋转键数:
    3
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.5
  • 拓扑面积:
    46.6
  • 氢给体数:
    0
  • 氢受体数:
    4

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • NK1 and NK3 antagonists
    申请人:O'Neill T. Brian
    公开号:US20050256164A1
    公开(公告)日:2005-11-17
    The invention is to a compound exhibiting neurokinin inhibitory properties, a pharmaceutical composition comprising same and a method of treatment for neurokinin-mediated conditions.
    这项发明涉及一种具有神经激肽抑制性能的化合物,包括该化合物的药物组合物以及用于神经激肽介导疾病的治疗方法。
  • Piperidine derivative, process for producing the same, and use
    申请人:Ikeura Yoshinori
    公开号:US20060167052A1
    公开(公告)日:2006-07-27
    The present invention provides a compound represented by the formula: wherein Ar is an aryl group, an aralkyl group or an aromatic heterocyclic group, each of which may be substituted, R 1 is a hydrogen atom, an optionally substituted hydrocarbon group, an acyl group or an optionally substituted heterocyclic group, X is an oxygen atom or an optionally lo substituted imino group, Z is an optionally substituted methylene group, Ring A is an optionally further substituted piperidine ring, and Ring B is an optionally substituted aromatic ring, provided that when Z is a methylene group substituted with an oxo group, R 1 is not a methyl group, and 15 when Z is a methylene group substituted with a methyl group, Ring B is a substituted aromatic ring, or a salt thereof, which is a novel piperidine derivative having excellent antagonistic action for a tachykinin receptor and useful as a medicament, particularly an agent for preventing and/or treating urinary frequency and/or urinary incontinence.
    本发明提供了一种化合物,其表示为以下式子:其中Ar是芳基、芳基烷基或芳香杂环基,每个基团都可以被取代,R1是氢原子、可选取代的碳氢基团、酰基或可选取代的杂环基团,X是氧原子或可选取代的亚胺基团,Z是可选取代的亚甲基团,环A是可选进一步取代的哌啶环,环B是可选取代的芳香环,但当Z是取代有氧基的亚甲基团时,R1不是甲基基团,而当Z是取代有甲基基团的亚甲基团时,环B是取代的芳香环,或其盐。该化合物是一种新型哌啶衍生物,具有优异的缓解速激肽受体拮抗作用,可用作药物,特别是用作预防和/或治疗尿频和/或尿失禁的药剂。
  • Fused Triazole Tachykinin Receptor Antagonists
    申请人:DeVita Robert J.
    公开号:US20090221611A1
    公开(公告)日:2009-09-03
    The present invention is directed to certain fused triazole compounds which are useful as neurokinin-1 (NK-I) receptor antagonists, and inhibitors of tachykinin and in particular substance P- The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including emesis, urinary incontinence, depression, and anxiety.
    本发明涉及某些融合的三唑化合物,它们可用作神经激肽-1(NK-I)受体拮抗剂和快速激肽,特别是物质P的抑制剂。本发明还涉及包含这些化合物作为活性成分的制药配方以及这些化合物及其配方在治疗某些疾病,包括呕吐、尿失禁、抑郁症和焦虑症方面的用途。
  • Cycloalkyl Keto Piperidine Tachykinin Receptor Antagonists
    申请人:DeVita J. Robert
    公开号:US20080076783A1
    公开(公告)日:2008-03-27
    The present invention is directed to certain piperidine compounds which are useful as neurokinin-1 (NK-1) receptor antagonists, and inhibitors of tachykinin and in particular substance P. The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including emesis, urinary incontinence, depression, and anxiety.
    本发明涉及某些哌啶化合物,其作为神经激肽-1(NK-1)受体拮抗剂和快速激肽,特别是物质P的抑制剂是有用的。本发明还涉及包含这些化合物作为活性成分的制药配方,并且涉及将这些化合物及其配方用于治疗某些疾病,包括呕吐、尿失禁、抑郁症和焦虑症。
  • Piperidine derivative and use thereof
    申请人:Ikeura Yoshinori
    公开号:US20070149570A1
    公开(公告)日:2007-06-28
    The present invention relates to a compound represented by the formula: wherein Ar is a phenyl group optionally having substituent(s), R 1 is a hydrogen atom, a hydrocarbon group optionally having substituent(s), an acyl group or a heterocyclic group optionally having substituent(s), R 2 is a hydrogen atom, a C 1-6 alkyl group optionally having substituent(s) or a C 3-6 cycloalkyl group optionally having substituent(s), Z is a methylene group optionally having a C 1-6 alkyl group, ring A is a piperidine ring optionally further having substituent(s), ring B and ring C are benzene rings optionally further having substituent(s), and R 2 optionally form a ring together with the adjacent substituent on the ring B, except the compounds represented by the formula: or a salt thereof. The compound of the present invention has a superior tachykinin receptor antagonistic action, particularly a substance P receptor antagonistic action, and is useful as a pharmaceutical agent, for example, tachykinin receptor antagonist, an agent for the prophylaxis or treatment of lower urinary tract symptoms, gastrointestinal diseases or central nerve diseases.
    本发明涉及一种化合物,其表示为以下式子: 其中Ar是苯基,可选地具有取代基;R1是氢原子,烃基,可选地具有取代基,酰基或杂环基,R2是氢原子,C1-6烷基,可选地具有取代基或C3-6环烷基,可选地具有取代基,Z是亚甲基,可选地具有C1-6烷基,环A是哌啶环,可选地具有进一步的取代基,环B和环C是苯环,可选地具有进一步的取代基,R2可选地与环B上相邻的取代基一起形成环,但不包括以下式子所表示的化合物或其盐: 本发明的化合物具有优良的速激肽受体拮抗作用,特别是物质P受体拮抗作用,并且可用作药物,例如速激肽受体拮抗剂,预防或治疗下尿路症状,胃肠疾病或中枢神经疾病的药剂。
查看更多